The efficacy of flecainide acetate in suppressing ventricular premature contractions in 14 patients was evaluated in a double-blind, cross-over, placebo controlled, randomized and balanced study. Each treatment period was 2 weeks followed by a 3-4 d placebo washout period and the study lasted 5 weeks. Flecainide was given in a dose of 200 mg twice daily.
Introduction
Flecainide acetate is a recently introduced Class 1 antiarrhythmic compound (Banitt et al., 1977; Cowan & Vaughan Williams, 1981) . Flecainide has several favourable pharmokinetic properties which include almost complete oral absorption, minimal first pass metabolism and a relatively long elimination half-life of 7-22 h (mean 14 h) .
Several animal studies showed that flecainide suppresses experimentally induced ventricular arrhythmias in dogs, mice (Schmid et al., 1975) and pigs (Verdouw et al., 1979) . Evaluation of the antiarrhythmic efficacy of flecainide in open studies in patients showed marked suppression of ventricular premature contractions (VPCs) (Hoback et al., 1978; Bender et al., 1979; Somani, 1980) . This study was designed to assess the value of oral flecainide in suppressing frequent VPCs. The effectiveness of flecainide in controlling supraventricular arrhythmias and repetitive VPCs, including couplets, salvos and non-sustained ventricular tachycardia, was also evaluated. The adverse effects of flecainide were also noted, including a proarrhythmic effect which was mentioned in a previous publication (Muhiddin et al., 1982) . Haematological and biochemical variables were monitored during the study to assess the safety of flecainide.
Methods

Patients
Fifteen non-hospitalized patients with frequent VPCs participated in the study. The patients were 7 males and 7 (non-pregnant) females, aged between 30-72 y and weighing 54-90 kg. The patients chosen fulfilled the following criteria: (a) having chronic stable VPCs with an average of more than 500 VPCs (aberrant QRS complexes) in 24 h as documented by each of the three preliminary 24 h ambulatory electrocardiograms (24 h ECG); (b) free from other antiarrhythmic therapy for at least 2 weeks prior to the study; (c) absence of heart failure; (d) absence of second degree or greater AV block, bundle branch block or distal block; (e) no history of myocardial infarction within 6 weeks before entry to the study; (f) absence of clinically significant endocrine, haematological, gastrointestinal, hepatic or renal abnormalities.
Design and protocol of the study
The study was double-blind, cross-over, placebo controlled, randomized and balanced. It analysed by a high speed analyser (Pathfinder-I Revnold Medical Electronics), and the minimum and maximum heart rates and numbers of normal and abnormal complexes/h recorded (Muhiddin, 1983 Four patients were withdrawn from the study because of long attacks of supraventricular tachycardia while on placebo (patient 4), and severe dizziness associated with flecainide therapy (patients 9 and 11). Patient 7 decided not to continue the trial because of his job. Table II. A significant reduction in the total number of QRS complexes in a 24 h period was observed during the active compared with placebo treatment (P < 0.05). In comparison with placebo, flecainide reduced the number of aberrant and premature aberrant QRS complexes (P<0.01), which was associated with improvement of symptoms. The percentage reduction in aberrant QRS complexes was 85.4 ± 4.3% (mean-± s.e.m.) and in premature aberrant complexes was 93.2 ± 2.3% (Table III) . Flecainide did not change significantly the number of R on T pauses and runs of supraventricular tachycardia (SVT)/24 h. The total number of episodes of ventricular tachycardia or salvos (which included couplets or more; VT/S) in 24 h was not reduced significantly. Out of 10 patients included in the interpretation of the results, seven had a lower incidence ofVT/S during flecainide treatment, while two had a higher incidence and one patient did not have this arrhythmia during either treatment.
Minimum heart rate did not change significantly with flecainide therapy. Maximum heart rate decreased in all 10 patients, the mean values ranged between 126-135 beats/min during the 3 visits whilst on the placebo course, compared with 115-116 beats/ min during the visits on flecainide therapy (P < 0.01).
Pulse rate and blood pressure Neither radial pulse rate (measured clinically) nor blood pressure (systolic and diastolic) changed significantly during flecainide therapy in comparison with placebo (Tables II and III) .
Serum concentration offlecainide
During the flecainide treatment period, mean trough concentrations of flecainide were 502, 779 and 888 ng/ ml over the three visits, while mean peak concentrations were 791, 1193 and 1187 ng/ml, respectively.
Haematology and biochemistry
Haematological and biochemical screening tests did not manifest any abnormality after 2 weeks of flecainide therapy.
Adverse effects
All patients investigated had adverse effects during flecainide therapy varying from mild to moderate and severe (Table IV) . Patient 6 complained of dizziness after receiving the second dose offlecainide. However, her physical examination in the first visit during the flecainide course revealed no indication for discontinuation of the study. The 24 h ECG recording, for that visit, showed three episodes of ventricular tachycardia, associated with dizziness, lasting up to 30 s at a rate of 130-165 beats/min (Figure 2 ). On the day of this recording the trough serum concentration of flecainide was 714 ng/ml and the peak concentration was 1183 ng/ml. The QRS duration increased from 100 milliseconds (ms), before flecainide, to 140 ms, during flecainide treatment. The QT interval prolonged from 420 ms to 480 ms, the QTc (QT/R-R (s)1/2) increased from 449 ms to 524 ms, the JT interval (QT minus QRS) prolonged from 320 ms to 340 ms and JTc (QTc minus QRS) prolonged from 349 ms to 384 ms. Flecainide was discontinued and no further episode of ventricular tachycardia was documented.
The most frequent adverse effects were dizziness, blurred vision and nausea. Severe dizziness was the reason to withdraw patients 9 and 11 from the study. Blurred vision, which was transient and occurred usually between 2 and 4 h after the tablet ingestion, did not require withdrawal from the study. Among the adverse effects reported in the study during flecainide therapy were headache (4 patients), chest pain (3 patients), lethargy (2 patients) and numbness of the lips (2 patients). One patient complained of involun- 
Discussion
Efficacy against ventricular arrhythmias
In this study, flecainide significantly reduced the frequency of aberrant and premature aberrant QRS complexes. The reduction seemed to be a genuine drug effect rather than due to naturally occurring spontaneous variability of VPC count between days (Morganroth et al., 1978) . This is particularly likely because of the increase in the frequency of most arrhythmias during the washout period following treatment with flecainide. Furthermore, Morganroth and co-workers (1978) postulated that when comparison is made between three 24 h control monitoring sessions and three 24 h periods of drug test monitoring, a reduction of greater than 65% in mean hourly VPC count is necessary to imply that the suppression is due to the drug's action. The percentage reduction achieved in this study was much higher than the limit set by these authors. These results are similar to those obtained by other investigators who found between 90 and 100% suppression in the frequency of VPCs during flecainide therapy (Anderson et al., 1981; Duff et al., 1981; Granrud et al., 1981; Bluschke et al., 1982; Duran et al., 1982; Hodges et al., 1982; Klempt et al., 1982; Abitbol et al., 1983; Salerno et al., 1983) . In this study, flecainide reduced the number of episodes of VT/S (repetitive VPCs) in 7 out of 10 patients but this did not reach statistical significance. In other reports there has been a reduction or elimination of repetitive VPCs by an average of 90-100% (Anderson et al., 1981; Duff et al., 1981; Duran et al., 1982; Hodges et al., 1982; Salerno et al., 1983) . Furthermore, it has been shown that oral flecainide is more effective than mexiletine (Klempt et al., 1982) , quinidine (Morganroth et al., 1983; Salerno et al., 1983) and disopyramide (Kjekshus et al., 1984) (Duran et al., 1982) or little effect on JTc (Salerno et al., 1983) . In this case symptomatic episodes of ventricular tachycardia developing in association with these ECG changes suggest that this arrhythmia was related to slowing of conduction. This complication is probably dose related. Winkle et al. (1981) reported similar arrhythmias associated with encainide therapy, which they suggest could be due to a similar mechanism. Single cases of ventricular tachycardia, not of the 'torsade de pointes' type, associated with QTc prolongation induced by flecainide were reported by Lui et al. (1982) and Hohnloser et al. (1983) . Nathan et al. (1983) reported 6 other cases of cardiac arrhythmias associated with flecainide treatment. Several other adverse effects were noted with flecainide treatment (Table 4) . Dizziness was a frequent complaint (in 9 patients) which was not associated with frequent VPCs or any other arrhythmia when the patients were receiving flecainide except in patient 6. In spite of high serum flecainide concentrations in 5 patients, none ofthem had serious adverse effects that necessitated stopping the medication. In this study, blurred vision was a common adverse effect, reported by 7 patients. It might be considered as an anticholinergic adverse effect of flecainide; however, no other anticholinergic effects, such as urinary retention or hesitancy, were notified in the study. Dry mouth was reported by one patient but this occurred during both active and placebo treatments. Other investigators have also reported dryness of the mouth among the adverse effects of intravenous flecainide in an open study (Abitbol et al., 1983) . Although these adverse effects could be related to anticholinergic activity, flecainide did not produce anticholinergic effects in guinea pigs (Riker Laboratories, data on file). In addition, previous results (Muhiddin & Turner, 1983) have shown that intravenous flecainide, in a double-blind study, did not produce a significant effect in respect ofdry mouth in normal healthy volunteers. The high incidence of adverse effects in this study may be partly due to associated high serum concentrations of flecainide observed in this group of patients.
After 2 weeks of flecainide therapy no obvious changes from baseline were noted in any haematological or biochemical variable. However, longer periods of monitoring would appear prudent.
In summary, this study showed that flecainide was more effective in controlling ventricular than supraventricular arrhythmias. This was associated with improvement of symptoms. Flecainide therapy is not free from risk of development of serious arrhythmias. Several other adverse effects, varying between mild to severe, were also noted with flecainide treatment. Since the aim of antiarrhythmic therapy is not only the elimination of arrhythmias, but also an improvement in prognosis, the value of flecainide in the management of patients at risk of sudden cardiac death remains to be seen.
